President & CEO
Professor Alan Boyd began his 30 years’ pharmaceutical career with Glaxo Group Research Ltd. From 1988 he led ICI’s cardiovascular medical research team, later assuming the role of Director of Clinical and Medical Affairs at ICI Pharma, Canada.
In 1999, after four years as Head of Medical Research for Zeneca Pharmaceuticals, he became Director of Research and Development for Ark Therapeutics Ltd where he was responsible for delivering the majority of key development milestones that have shaped the company. In particular, he led the development of their gene-based medicines portfolio.
In April 2005, he left to set up Boyd Consultants. The focus of which is to aid and support early-stage life-science-based companies and universities particularly in the translation and development of their research ideas into therapeutics. His contribution to medicines development has resulted so far in around fifteen products being licensed as prescription medicines and this includes seven cell and gene therapies.
In 2009, Professor Boyd was appointed an Honorary Professor in the College of Medical and Dental Sciences at the University of Birmingham Medical School. He is also a Fellow at the Faculty of Pharmaceutical Medicine, Royal College of Physicians, where he has undertaken many officer roles over several years. This culminated in him becoming the President of the organisation from 2015 to 2018. Through his work at the Faculty, he has made significant contributions to the establishment of the specialty training programme in pharmaceutical medicine, which has now resulted in around 400 post-graduate trainees receiving a CCT in the specialty.
In 2021, he was awarded a Fellowship of the Academy of Medical Sciences in recognition of his significant involvement in supporting the development of medicines across several therapeutic areas, most notably in the field of cell and gene advanced therapeutics.
Crewe Business Park
CW1 6GL, UK
T +44 (0)1270 270010
F +44 (0)1270 253832
M +44 (0)7899 873150
- +44 (0)1270 270010